These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37460807)

  • 1. Advances in bio-immunotherapy for castration-resistant prostate cancer.
    Lin C; Chen Y; Shi L; Lin H; Xia H; Yin W
    J Cancer Res Clin Oncol; 2023 Nov; 149(14):13451-13458. PubMed ID: 37460807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer.
    Bansal D; Reimers MA; Knoche EM; Pachynski RK
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33477569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
    Sun BL
    Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
    Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
    Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
    Heidegger I; Necchi A; Pircher A; Tsaur I; Marra G; Kasivisvanathan V; Kretschmer A; Mathieu R; Ceci F; van den Bergh RCN; Thibault C; Tilki D; Valerio M; Surcel C; Gandaglia G;
    Eur Urol Oncol; 2021 Oct; 4(5):745-754. PubMed ID: 33243663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Past, Current, and Future of Immunotherapies for Prostate Cancer.
    Boettcher AN; Usman A; Morgans A; VanderWeele DJ; Sosman J; Wu JD
    Front Oncol; 2019; 9():884. PubMed ID: 31572678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.
    Karantanos T; Corn PG; Thompson TC
    Oncogene; 2013 Dec; 32(49):5501-11. PubMed ID: 23752182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression in immunotherapy for advanced prostate cancer.
    Liang H; Liu Y; Guo J; Dou M; Zhang X; Hu L; Chen J
    Front Oncol; 2023; 13():1126752. PubMed ID: 36925917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C; Abboud K
    Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy.
    Shiota M; Yokomizo A; Eto M
    Front Oncol; 2015; 5():304. PubMed ID: 26793621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolving landscape of immunotherapy in advanced prostate cancer.
    Patel VG; Oh WK
    Immunotherapy; 2019 Jul; 11(10):903-912. PubMed ID: 31161846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
    de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
    BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
    Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
    Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.